The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2025 at "Hematological Oncology"
DOI: 10.1002/hon.70116
Abstract: Despite allo‐HSCT being the primary curative treatment for high‐risk AML, relapse‐free survival (RFS) remains suboptimal due to high relapse incidence. Our research focuses on optimizing the conditioning regimen by incorporating Mitoxantrone Hydrochloride Liposome (Lipo‐MIT), a… read more here.
Keywords: mitoxantrone hydrochloride; conditioning regimen; lipo mit; high risk ... See more keywords
Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204337
Abstract: Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous and aggressive group of lymphoma, representing 25%~30% of non-Hodgkin lymphomas in China. The standard initial treatments for PTCL include CHOP or CHOEP, but the long-term survival is… read more here.
Keywords: treatment; cell lymphoma; lipo mit; cell ... See more keywords
Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-209224
Abstract: Background : Natural killer/T-cell lymphoma (NKTCL) is a rare and highly aggressive subtype of non-Hodgkin lymphoma (NHL) strongly associated with Epstein-Barr virus (EBV) infection and characterized by extranodal involvement. Survival outcome in patients with relapsed… read more here.
Keywords: phase study; lipo mit; rate orr; study ... See more keywords
Mitoxantrone Hydrochloride Liposome, Proteasome Inhibitors, Pomalidomide and Dexamethasone Regimen in Multiple Myeloma Patients with Extramedullary Plasmacytoma in China
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210174
Abstract: Background Extramedullary plasmacytoma (EMP), as a poor prognostic factor, frequently occurres in multiple myeloma (MM) with adverse prognosis, more prospective longitudinal studies should be carried out for clinical practice. Mitoxantrone hydrochloride liposome (Lipo- MIT) has… read more here.
Keywords: multiple myeloma; mvpd mkpd; lipo mit; study ... See more keywords
Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5423
Abstract: Background: Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of mature aggressive T-cell non-Hodgkin's lymphomas characterized by poor prognosis, which highlights the urgent need for novel therapeutic. The combination of gemcitabine, cisplatin and dexamethasone (GDP)… read more here.
Keywords: cell lymphoma; lipo mit; cell; study ... See more keywords
Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-776
Abstract: Background Outcomes for patients with relapsed/refractory (R/R) peripheral T-cell lymphomas (R/R-PTCLs) are poor. Single agent overall response rates (ORRs) for R/R-PTCLs generally fall within the 20-35% range, with a median progression-free survival (PFS) of less… read more here.
Keywords: chidamide group; mit group; lipo mit; group ... See more keywords